MarketBeat
30 Jul 2026, 04:05 UTC · 8w ago
Verdict
Headline takes no side. We score GKOS +1.00 across five claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Glaukos raised its full-year 2026 net sales guidance to a range of $680 million to $700 million, up from $620 million to $635 million.
So whatA significant upward revision of annual revenue guidance typically triggers a positive re-rating of the stock price.
More positive than 99% of claims this week
The iDose TR product contributed approximately $74 million to U.S. glaucoma revenue in Q2, with projected full-year 2026 revenue between $275 million and $280 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 98% of claims this week
The company's corneal health franchise grew 48% in Q2, driven by $11 million in Epioxa sales, with overall 2026 franchise growth projected at approximately 20%.
More positive than 86% of claims this week
Gross margin for the second quarter was approximately 85%, with expectations for modest additional accretion through the remainder of 2026.
So whatExpanding margins indicate improving operational efficiency and pricing power as higher-margin products gain share.
More positive than 64% of claims this week
Management expects some volatility in third-quarter performance as Epioxa transitions to a permanent product-specific J-code.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company reported record net sales, exceeded management expectations, and raised its full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−4.2%
Price is moving against the score
$154.82 vs $161.66 close before publication (Jul 29) · not market-adjusted
GKOS chart →
